West Pharmaceutical Services, Inc. WST
412.86 USD +0.31 (+0.08%)
At closeNov 11, 2026, 4:00 PM EST
412.86 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
411.86 Day range 415.85
223.83 52-week range 438.27
- YTD
- +50.05%
- 1 year
- +48.83%
News
prnewswire.com West to Participate in Upcoming Investor Conference EXTON, Pa., Nov. 4, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will…
defenseworld.net West Pharmaceutical Services, Inc. $WST Stock Position Raised by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 39.8% in the undefined quarter, according to the company in its most recent…
benzinga.com Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494 Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $412 to $494.
benzinga.com TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500 TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $420 to $500.
benzinga.com Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500 Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.- benzinga.com Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480 Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $440 to $480.
benzinga.com West Pharmaceutical Servs Q3 2026 Earnings Call Transcript West Pharmaceutical Servs (NYSE:WST) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com West Pharmaceutical Servs Sees Q4 Adj EPS $2.22-$2.32 vs $2.27 Est; Sees Sales $820.000M-$830.000M vs $826.736M Est West Pharmaceutical Servs (NYSE:WST) is looking for Q4 Adj EPS of $2.22-$2.32 vs $2.27 analyst estimate. sees sales of $820.000 million-$830.000 million vs $826.736 million analyst estimate.
benzinga.com West Pharmaceutical Servs Q3 Adj. EPS $2.66 Beats $2.19 Estimate, Sales $874.500M Beat $825.700M Estimate West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $2.19 by 21.46 percent. This is a 35.71 percent increase over earnings…- benzinga.com West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 analyst estimate..
benzinga.com This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.
benzinga.com Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’ CNBC traders picked WST, JPM, META and IYE; analysts raised WST and META targets, while JPM missed Q3 earnings and revenue estimates.
benzinga.com TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420 TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.- benzinga.com Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440 Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.
benzinga.com This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Analysts upgraded MetLife, Brinker, Plexus, West Pharma and Omeros, raising ratings and price targets.- benzinga.com Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400 Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.
benzinga.com UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415 UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
benzinga.com Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412 Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.
benzinga.com Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425 Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.
benzinga.com West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.
benzinga.com Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs…
benzinga.com Earnings Scheduled For July 23, 2026 Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…- benzinga.com West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345…
benzinga.com West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..- benzinga.com West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est West Pharmaceutical Servs (NYSE:WST) is looking for Q3 Adj EPS of $2.14-$2.24 vs $2.12 analyst estimate. sees sales of $820.000 million-$835.000 million vs $815.707 million analyst estimate.
- benzinga.com West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.08 by 13.94 percent. This is a 28.8 percent increase over earnings…
- benzinga.com West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko https://www.sec.gov/ix?doc=/Archives/edgar/data/0000105770/000010577026000093/wst-20260714.htmThe terms of the Agreements are substantially similar to the terms of the Amended and Restated Technology…
- benzinga.com BNP Paribas Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $447 BNP Paribas analyst Curtis Moiles initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Outperform rating and announces Price Target of $447.
- benzinga.com Morgan Stanley Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $365 Morgan Stanley analyst Kallum Titchmarsh maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $325 to $365.
- benzinga.com Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $410 Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $390 to $410.
- benzinga.com Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390 Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $350 to $390.
benzinga.com This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Wall Street analysts upgraded AJG & BRC. See analyst rating changes & how they view BRC stock.- benzinga.com Barclays Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400 Barclays analyst Luke Sergott upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $310 to $400.
- benzinga.com Stephens & Co. Reiterates Overweight on West Pharmaceutical Servs, Maintains $360 Price Target Stephens & Co. analyst Steven Etoch reiterates West Pharmaceutical Servs (NYSE:WST) with a Overweight and maintains $360 price target.
- benzinga.com Morgan Stanley Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $325 Morgan Stanley analyst Kallum Titchmarsh maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $315 to $325.
benzinga.com Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.
benzinga.com Investors Await Damage Assessment After West Pharmaceutical Cyberattack West Pharmaceutical disclosed a cyberattack that disrupted operations as analysts assess financial risks and recovery progress.- benzinga.com Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $310 Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $275 to $310.
benzinga.com West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1 West Pharmaceutical beats Q1 estimates on strong GLP-1 demand, raises 2026 outlook, and authorizes $1 billion buyback amid solid growth.
benzinga.com Nasdaq 100 Eases From Records As Software Stocks Plunge: Stock Market Today U.S. stocks dipped as Iran-Hormuz tensions lifted oil, IBM and ServiceNow cratered, and defensive sectors led a rotation
benzinga.com Comcast, Molina Healthcare, STMicroelectronics And Other Big Stocks Moving Higher On Thursday U.S. stocks were lower on Thursday, with the Dow Jones dropping over 200 points. Comcast's strong earnings caused its shares to rise 6.7%.
benzinga.com West Pharmaceutical Servs Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Market-Moving News for April 23rd WST: 16% | West Pharmaceutical Services shares are trading higher after the company reported better-than-expected Q1 financial results and raised FY26 guidance above estimates. NOW: -15% | ServiceNow
- benzinga.com Earnings Scheduled For April 23, 2026
- benzinga.com West Pharmaceutical Servs Sees Q2 Adj EPS $2.05-$2.12 vs $2.00 Est; Sees Sales $830.000M-$850.000M vs $818.537M Est West Pharmaceutical Servs (NYSE:WST) is looking for Q2 Adj EPS of $2.05-$2.12 vs $2.00 analyst estimate. sees sales of $830.000 million-$850.000 million vs $818.537 million analyst estimate.
- benzinga.com West Pharmaceutical Servs Sees Q2 Sales $830.000M-$850.000M vs $818.537M Est West Pharmaceutical Servs (NYSE:WST) sees Q2 sales of $830.000 million-$850.000 million vs $818.537 million analyst estimate.
- benzinga.com West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $7.85-$8.20 to $8.40-$8.75 vs $8.01 Est; Raises FY2026 Sales Guidance from $3.215B-$3.275B to $3.295B-$3.350B vs $3.249B Est Outlook for Full-Year and Second Quarter 2026Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion, up from $3.215 billion to $3.275 billion and full-year 2026…
- benzinga.com West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $7.79-$8.14 to $8.15-$8.50 vs $7.91 Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $7.79-$8.14 to $8.15-$8.50 vs $7.91 analyst estimate..
- benzinga.com West Pharmaceutical Servs Q1 Adj. EPS $2.13 Beats $1.68 Estimate, Sales $844.900M Beat $779.974M Estimate West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.68 by 26.79 percent. This is a 46.9 percent increase over earnings…